semaglutide constipation lawsuit in louisiana glp-1 law firm GLP-1 RA GenBioPro CEO Evan Masingill told

GLP-1 weight loss drug use almost doubles in nine months Disrupting food behaviour Chantel Kennaugh, head of public sector and nutrition, GB, at Worldpanel by Numerator, said GLP-1 had become a mainstream force in a short space of time

LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial Multi-receptor agonists that target the glucagon, glucose-dependent insulinotropic polypeptide (GIP), and glucagon-like peptide 1 (GLP-1) receptors may improve outcomes in type 2 diabetes because this condition is linked to hyperglycemia and obesity

New multi-agonists are in development, so there may be more brands and variations on the market in the next year or two

What if I am interested in weight loss

They confirm that the lack of UTI risk is not merely a byproduct of better glucose management